HARMONY BIOSCIENCES OPENS APPLICATIONS FOR 2022 PROGRESS AT THE HEART PROGRAM

Method will award funding to choose applications from non-financial gain corporations addressing disparities in exceptional neurological sickness and slumber disorder communities

PLYMOUTH Assembly, Pa., April 7, 2022 /PRNewswire/ — Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to acquiring and commercializing progressive therapies for people residing with rare neurological health conditions, is now accepting applications for the next once-a-year Progress at the Coronary heart system, which resources progressive applications that handle disparities, injustice, and inequities in the exceptional neurological sickness and slumber ailment communities.

People with rare neurological diseases normally have constrained entry to prognosis, procedure, and treatment. The disparities can be even higher for folks from underrepresented ethnic or other minority groups in both equally accessibility to treatment and underrepresentation in analysis and clinical trials. Alongside one another, these disparities make timely analysis and ample therapy exponentially more difficult, possibly resulting in serious wellbeing consequences.¹ Slumber deficiencies, which contain insufficient or long slumber duration, lousy slumber high-quality, and irregular timing of sleep, are disproportionately dispersed among the populations that encounter wellness disparities in the United States.²

“At Harmony Biosciences, we are fully commited to supporting initiatives that purpose to counteract the systemic inequity, injustice and unequal procedure of underserved communities,” said Cate McCanless, Harmony’s Chief Corporate Affairs Officer. “In 2021, we released Development at the Heart to acknowledge courses that tackle these aims and we’re happy to continue on our guidance for local community and schooling-centered methods that boost the life of persons living with scarce neurological disorders and their families.”

Harmony Biosciences is now accepting 2022 Development at the Heart programs that emphasis on one or extra of the pursuing groups:

Story carries on

• Local community Applications: Individuals-centered, local community-led systems to strengthen consciousness and remedy in the sleep dysfunction and exceptional neurological health conditions with rest deficiencies communities and assist attain higher equality for underrepresented ethnic or other minority groups

• Schooling: Standard public and health care supplier schooling and applications that improve recognition and reduce time to prognosis of rest diseases and unusual neurological diseases with slumber deficiencies uncovered in underrepresented ethnic or other minority groups

• Public Health: Generation of or modifications to public policies that impression underrepresented ethnic or other minority groups

• Other proposals that assist accomplish bigger equality inside of unusual neurological ailment communities

Harmony Biosciences has two open up application durations from April 7-Might 20 and from May 31-August 19. Notifications will be despatched to awardees by July and Oct 2022, respectively. The apps will be reviewed by a cross-purposeful team of Harmony Biosciences employees. Proposals will be evaluated primarily based on a common established of critique requirements, which will involve the high quality of the software, creative imagination of the remedy, and the organization’s infrastructure and past software successes. For a lot more details or to submit an application, be sure to go to https://www.harmonybiosciences.com/funding-systems/development-at-the-heart. Any additional thoughts can be directed to [email protected].

About Harmony Biosciences

Harmony Biosciences is a commercial phase pharmaceutical organization headquartered in Plymouth Assembly, PA. The Firm was set up by Paragon Biosciences, LLC, and is focused on giving novel therapy solutions for people residing with uncommon neurological ailments who have unmet medical desires. For extra information and facts on Harmony, remember to go to the company’s web site: www.harmonybiosciences.com.

Harmony Biosciences Media Contact:
Nancy Leone
215-891-6046
[email protected]

Harmony Biosciences Trader Contact:
Patti Lender
ICR Westwicke
415-513-1284
[email protected]

1. #RiseForRare. The Rare Disease Range Coalition site: https://www.rarediseasediversity.org. Accessed March 16, 2021.

2. Jackson CL, Walker JR, Brown MK, Das R, Jones NL. A workshop report on the causes and outcomes of rest wellbeing disparities. Sleep. 202043(8)zsaa037.

Look at authentic articles to down load multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-opens-apps-for-2022-progress-at-the-heart-plan-301519244.html

Resource Harmony Biosciences